Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Open Access
- 5 October 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 396 (10259), 1345-1352
- https://doi.org/10.1016/s0140-6736(20)32013-4
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicinesJournal of Genetics and Genomics, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- ProTox-II: a webserver for the prediction of toxicity of chemicalsNucleic Acids Research, 2018
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common MarmosetThe Journal of Infectious Diseases, 2015
- Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell CultureAntimicrobial Agents and Chemotherapy, 2014
- Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in ChildrenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitorsJournal of Theoretical Biology, 2008
- In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compoundsJournal of Clinical Virology, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004